Transplantation Proceedings
Volume 36, Issue 6 , Pages 1728-1731, July 2004

Humoral sensitization against rejected grafts: Specific antibodies to graft immunogenic amino acid triplets

  • A. Iniotaki-Theodoraki

      Affiliations

    • National Tissue Typing Center, General Hospital of Athens, Athens, Greece (A.I.-T., E.K., M.A., C.S.-G.)
    • Corresponding Author InformationAddress reprint requests to Dr Aliki Iniotaki-Theodoraki, National Tissue Typing Center, General Hospital of Athens, 34 Davaki Street, 174 55, Alimos, Athens, Greece
  • ,
  • E. Kalogeropoulou

      Affiliations

    • National Tissue Typing Center, General Hospital of Athens, Athens, Greece (A.I.-T., E.K., M.A., C.S.-G.)
  • ,
  • M. Apostolaki

      Affiliations

    • National Tissue Typing Center, General Hospital of Athens, Athens, Greece (A.I.-T., E.K., M.A., C.S.-G.)
  • ,
  • I.N. Doxiadis

      Affiliations

    • Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands (I.N.D.)
  • ,
  • C. Stavropoulos-Giokas

      Affiliations

    • National Tissue Typing Center, General Hospital of Athens, Athens, Greece (A.I.-T., E.K., M.A., C.S.-G.)

Abstract 

Humoral sensitization against immunogenic amino acid (aa) triplets expressed on a rejected graft was analyzed in 83 retransplant candidates. All patients had lost a graft with HLA-A,-B mismatches. The alloantibodies were detected by a complement-dependent cytotoxicity (CDC) technique and an ELISA method in parallel; they were classified as HLA graft-specific (GS) and non-GS antibodies. The aa triplet specificity of the antibodies was assessed using the HLAMatchmaker algorithm. HLA class I antibodies were detected in 74 of 78 (94%) cases, including GS reactivity in 55 (74.3%) and non-GS in 72 (97.2%), either alone (n = 19) or in parallel with GS antibodies (n = 53). For all HLA-GS-antibody-reactive patients, we defined the specificity against immunogenic aa triplets on the previous graft. Moreover, antibodies specific to graft aa triplets were observed within the non-GS antibodies among 19 of 19 and 28 of 53 cases, respectively. Therefore, aa triplet-specific antibodies against the rejected graft were present in all 74 cases with HLA class I antibodies. Antibodies against aa triplets expressed on all HLA class I–mismatched graft antigens were present in 73% of cases. The high extent of humoral alloreactivity against a rejected graft supports the decision to avoid repeated exposure to immunogenic aa triplet mismatches on a second graft. An accurate analysis for performed antibodies in these cases may be beneficial to select the most suitable second donor.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 

PII: S0041-1345(04)00670-0

doi:10.1016/j.transproceed.2004.06.005

Transplantation Proceedings
Volume 36, Issue 6 , Pages 1728-1731, July 2004